Literature DB >> 32827468

Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016.

Peter A Glynn1, Hongyan Ning2, Aakash Bavishi1, Priya M Freaney3, Sanjiv Shah4, Clyde W Yancy4, Donald M Lloyd-Jones3, Sadiya S Khan5.   

Abstract

BACKGROUND: Implementation of effective preventive interventions requires identification of high-risk individuals. We sought to define the distribution and trends of heart failure risk in the US population.
METHODS: We calculated 10-year predicted heart failure risk among a representative sample of US adults aged 30-79 years, without baseline cardiovascular disease, from the National Health and Nutrition Examination Surveys (NHANES) 1999-2016. We used the published Pooled Cohort Equations to Prevent Heart Failure (PCP-HF) model, which integrates demographic and risk factor data, to estimate 10-year heart failure risk. Participants were stratified by NHANES cycle, sex, age, and race/ethnicity and by 10-year heart failure risk, defined as low (<1%), intermediate (1% to <5%), and high (≥5%).
RESULTS: From 1999-2000 to 2015-2016, mean predicted 10-year heart failure risk increased significantly from 2.0% to 3.0% (P < .05) in the population, most notably among non-Hispanic black (2.1% to 3.7%) and non-Hispanic white (2.4% to 3.6%) men. In 2013-2016, 17.6% of the studied population was at high predicted 10-year heart failure risk. The prevalence of high predicted heart failure risk was highest among non-Hispanic black men (23.1%), followed by non-Hispanic white men (19.2%) and non-Hispanic white women (17.9%). DISCUSSION: Mean population risk of heart failure increased significantly from 1999-2016. A substantial proportion of US adults are at high 10-year heart failure risk (≥5%), particularly non-Hispanic black men. These data underscore the importance of identifiying individuals at increased heart failure risk for targeted prevention measures to reduce the future burden of heart failure.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Health disparities; Heart failure; Prevention; Risk stratification

Mesh:

Year:  2020        PMID: 32827468      PMCID: PMC7895865          DOI: 10.1016/j.amjmed.2020.07.025

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

1.  Data Resource Profile: The Cardiovascular Disease Lifetime Risk Pooling Project.

Authors:  John T Wilkins; Kunal N Karmali; Mark D Huffman; Norrina B Allen; Hongyan Ning; Jarett D Berry; Daniel B Garside; Alan Dyer; Donald M Lloyd-Jones
Journal:  Int J Epidemiol       Date:  2015-08-14       Impact factor: 7.196

2.  Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community.

Authors:  Vanessa Xanthakis; Danielle M Enserro; Martin G Larson; Kai C Wollert; James L Januzzi; Daniel Levy; Jayashri Aragam; Emelia J Benjamin; Susan Cheng; Thomas J Wang; Gary F Mitchell; Ramachandran S Vasan
Journal:  JACC Heart Fail       Date:  2016-07-06       Impact factor: 12.035

3.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

4.  Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance.

Authors:  Patricia P Chang; Lisa M Wruck; Eyal Shahar; Joseph S Rossi; Laura R Loehr; Stuart D Russell; Sunil K Agarwal; Suma H Konety; Carlos J Rodriguez; Wayne D Rosamond
Journal:  Circulation       Date:  2018-03-08       Impact factor: 29.690

5.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 7.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

8.  10-Year Risk Equations for Incident Heart Failure in the General Population.

Authors:  Sadiya S Khan; Hongyan Ning; Sanjiv J Shah; Clyde W Yancy; Mercedes Carnethon; Jarett D Berry; Robert J Mentz; Emily O'Brien; Adolfo Correa; Navin Suthahar; Rudolf A de Boer; John T Wilkins; Donald M Lloyd-Jones
Journal:  J Am Coll Cardiol       Date:  2019-05-21       Impact factor: 24.094

9.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

10.  Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.

Authors:  Matthew Griffin; Veena S Rao; Juan Ivey-Miranda; James Fleming; Devin Mahoney; Christopher Maulion; Nisha Suda; Krishmita Siwakoti; Tariq Ahmad; Daniel Jacoby; Ralph Riello; Lavanya Bellumkonda; Zachary Cox; Sean Collins; Sangchoon Jeon; Jeffrey M Turner; F Perry Wilson; Javed Butler; Silvio E Inzucchi; Jeffrey M Testani
Journal:  Circulation       Date:  2020-05-15       Impact factor: 29.690

View more
  8 in total

Review 1.  New strategies and therapies for the prevention of heart failure in high-risk patients.

Authors:  Michael M Hammond; Ian K Everitt; Sadiya S Khan
Journal:  Clin Cardiol       Date:  2022-06       Impact factor: 3.287

2.  Secular Trends in Prevalence of Heart Failure Diagnosis over 20 Years (from the US NHANES).

Authors:  George Cm Siontis; Deepak L Bhatt; Chirag J Patel
Journal:  Am J Cardiol       Date:  2022-03-28       Impact factor: 3.133

3.  Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018.

Authors:  Zachary H Hughes; Hongyan Ning; Sanjiv J Shah; Clyde W Yancy; John T Wilkins; Donald M Lloyd-Jones; Sadiya S Khan; Nilay S Shah
Journal:  Circ Heart Fail       Date:  2022-04-04       Impact factor: 10.447

4.  Association Between Dietary Fiber Intake and Heart Failure Among Adults: National Health and Nutrition Examination Survey 2009-2018.

Authors:  Hao Zhang; Zhibin Lin; Jun Chen; Daojing Gan; Haobin Zhou; Zhuang Ma; Xianghui Zeng; Yuting Xue; Xiao Wang; Qiong Zhan; Qingchun Zeng; Dingli Xu
Journal:  Front Cardiovasc Med       Date:  2022-05-17

5.  Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study.

Authors:  Michael C Wang; Bridget Dolan; Benjamin H Freed; Lourdes Vega; Nikola Markoski; Amy E Wainright; Bonnie Kane; Laura E Seegmiller; Katharine Harrington; Alana A Lewis; Sanjiv J Shah; Clyde W Yancy; Ian J Neeland; Hongyan Ning; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Front Cardiovasc Med       Date:  2021-11-29

6.  Gsα deficiency facilitates cardiac remodeling via CREB/ Bmp10-mediated signaling.

Authors:  Ping Yin; Dan Li; Qi Zhao; Mingming Cai; Zhenru Wu; Yujun Shi; Li Su
Journal:  Cell Death Discov       Date:  2021-12-14

7.  Mendelian randomization of circulating proteome identifies actionable targets in heart failure.

Authors:  Louis-Hippolyte Minvielle Moncla; Samuel Mathieu; Mame Sokhna Sylla; Yohan Bossé; Sébastien Thériault; Benoit J Arsenault; Patrick Mathieu
Journal:  BMC Genomics       Date:  2022-08-13       Impact factor: 4.547

8.  The Anti-inflammatory Effect of Chitosan Oligosaccharide on Heart Failure in Mice.

Authors:  Yubiao Zhang; Yu Wang; Yunen Liu; Tianxing Gong; Mingxiao Hou
Journal:  Biomed Res Int       Date:  2022-10-05       Impact factor: 3.246

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.